Protalix BioTherapeutics (NYSE:PLX) Upgraded by StockNews.com to Strong-Buy Rating

StockNews.com upgraded shares of Protalix BioTherapeutics (NYSE:PLX) from a buy rating to a strong-buy rating in a research note issued to investors on Thursday.

Protalix BioTherapeutics Stock Performance

PLX opened at $1.80 on Thursday. The business has a 50 day moving average of $1.35 and a 200-day moving average of $1.18. Protalix BioTherapeutics has a 52 week low of $0.82 and a 52 week high of $1.90.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC increased its holdings in shares of Protalix BioTherapeutics by 673.3% in the 2nd quarter. Squarepoint Ops LLC now owns 137,764 shares of the company’s stock worth $161,000 after purchasing an additional 119,949 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Protalix BioTherapeutics in the 2nd quarter worth $80,000. Ground Swell Capital LLC bought a new stake in shares of Protalix BioTherapeutics in the 2nd quarter worth $73,000. AQR Capital Management LLC bought a new stake in shares of Protalix BioTherapeutics in the 2nd quarter worth $67,000. Finally, Virtu Financial LLC bought a new stake in shares of Protalix BioTherapeutics in the 3rd quarter worth $44,000. Hedge funds and other institutional investors own 16.53% of the company’s stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.